Frederick Lowery

CULTURETECHLENS · “Culture, Clearly Seen.” · Black Cultural Intelligence

Research record

Frederick Lowery · Staged record CTL-P-1147 · Entity Depth Program · 605 words · Evidence grade: VERIFIED (canonical master, carried unchanged) · Researched 2026-10-25

Frederick M. Lowery's appointment as chief executive of Henry Schein, Inc. — the appointment that carries this record — was announced in January 2026 and took effect on March 2, 2026, when he succeeded Stanley M. Bergman, who remained as chairman of the board. The announcement release, carried by business wires and republished in the healthcare trade press, is the document that verifies this graph entry, and it frames the appointment as a succession prepared by the board's nominating and governance committee, chaired by Philip A. Laskawy, with a vice chair, Kurt P. Kuehn, named in the same announcement. Henry Schein is described in the release as a Fortune 500 company and the world's largest provider of healthcare solutions to dental and medical professionals, reporting 2024 sales of $12.7 billion, a workforce of approximately 24,000, operations or affiliates in thirty-three countries and territories, and more than one million customers.

Lowery came to the role from Thermo Fisher Scientific, where he was an executive vice president and president of the Laboratory Products and BioProduction business — a portfolio the release describes as spanning laboratory equipment, consumables, and production and purification solutions for life-science research, biopharmaceutical production, and diagnostic testing. In that role he also led the Fisher Scientific channel, Thermo Fisher's distribution business serving the healthcare, education and government, and industrial and applied markets. The release credits his leadership at Thermo Fisher with transformations using the company's Practical Process Improvement business system, and with performance across the COVID-19 pandemic period. His time in healthcare and distribution leadership totals, in the release's summary, more than twenty years.

The earlier career is stated in the same document, and this entry states it no more precisely than the document does: before joining Thermo Fisher, Lowery held positions at Maytag Corporation and General Motors, and he served as a division president at a former Thermo Fisher company. His education is likewise on the record in two degrees — a bachelor's degree in mechanical engineering from Tennessee Technological University and a master's degree in manufacturing management from Kettering University, the institution formerly known as GMI. Trade coverage of the appointment filed with the company's securities disclosures added the compensation structure of the hire, including a one-time cash bonus and a sign-on equity award with a three-year vesting schedule, details carried in the company's current report.

Bergman's statement in the announcement is the succession's stated rationale: that the board's process had identified in Lowery a leader whose experience across healthcare distribution, manufacturing, and technology fit the company's next plan cycle, named in the release as the BOLD+1 strategic plan, and that continuity would be supported by Bergman's continued chairmanship and by a transition period. The announcement also recorded the company's governance context: in 2025 the investment firm KKR had taken a significant minority stake in Henry Schein, with representatives joining the board.

In the CultureTechLens graph, Lowery's two edges place him on the Black Fortune 500 CEOs list and affiliate him with the Henry Schein institution record. The graph's known-for statement for him — leading Henry Schein's global distribution strategy — is the trade summary of the same appointment. This entry is deliberately confined to what the appointment record and its coverage support: a mechanical engineer by training, a distribution and laboratory-products executive by career, and, from March 2, 2026, the chief executive of the world's largest distributor to dental and medical practices. Where public profiles add that he is a Knoxville native, this entry notes the detail as it appears in profile coverage without resting any claim on it; the batch index records the limits of the public record consulted here.

Sources for this record

• Henry Schein Names Frederick M. Lowery as Chief Executive Officer — Savoy Network (Henry Schein announcement release)
  Claims supported: Master verification source: Henry Schein names Frederick M. Lowery CEO effective March 2, 2026, succeeding Stanley Bergman; Lowery was EVP and President, Laboratory Products and BioProduction, at Thermo Fisher Scientific; bachelor's in mechanical engineering from Tennessee Tech.
• Henry Schein Appoints Frederick M. Lowery as Chief Executive Officer — CityBiz (Henry Schein announcement release)
  Claims supported: Led the Fisher Scientific distribution channel; more than 20 years in healthcare; prior positions at Maytag and General Motors; master's in manufacturing management from Kettering University (formerly GMI); Bergman continues as Chairman; BOLD+1 strategic plan; succession led by the nominating and governance committee chaired by Philip A. Laskawy; KKR took a significant minority stake in 2025 with board representation; Henry Schein a Fortune 500 company with 2024 sales of $12.7 billion, approximately 24,000 team members, operations or affiliates in 33 countries and territories, and more than 1 million customers.
• Henry Schein Taps Distribution Veteran Frederick Lowery as CEO — Distribution Strategy Group
  Claims supported: Details from the company's SEC filing on the appointment: one-time cash bonus, sign-on restricted stock units vesting over three years, and relocation reimbursement; appointment coverage published January 14, 2026.

Citations

Published October 25, 2026, from the head-verified staged record in the Entity Depth Program (Batches 004–008). Source: CultureTechLens